The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it. More than 40 million people worldwide live with AIDS because of this virus, ...

The nonprofit Finding Hope for Frizzle aims to initiate a clinical trial of the gene therapy for FRRS1L disease in the second half of 2026.

A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...

New research from the University of Minnesota School of Dentistry and Masonic Cancer Center is providing important new insights into the structure of a human virus that causes blood cancer.

Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...

New research from the University of Minnesota School of Dentistry and Masonic Cancer Center is providing important new insights into the structure of ...

The last time I wrote about Abeona Therapeutics (ABEO) it was in a Seeking Alpha article entitled "Abeona: BLA Resubmission of Pz-Cel Gets Ball Rolling Towards Other Milestones." With respect to this ...

From a virus's point of view, invading our cells is a matter of survival. The virus makes a living by highjacking cellular processes to produce more of the proteins that make it up. From our point of ...

Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive ...